Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $46.65 Consensus Target Price from Brokerages

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been given a consensus rating of “Moderate Buy” by the nineteen analysts that are presently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $46.65.

Several research firms have recently weighed in on APLS. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $25.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, November 4th. Oppenheimer decreased their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. William Blair began coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating for the company. Finally, Robert W. Baird cut their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th.

Insider Transactions at Apellis Pharmaceuticals

In related news, CEO Cedric Francois sold 6,247 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $179,288.90. Following the sale, the chief executive officer now owns 307,415 shares in the company, valued at $8,822,810.50. This represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Caroline Baumal sold 2,816 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the transaction, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. This trade represents a 4.82 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,308 shares of company stock worth $511,406. Company insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. True Wealth Design LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter worth $27,000. Capital Performance Advisors LLP acquired a new stake in Apellis Pharmaceuticals during the third quarter valued at $56,000. KBC Group NV increased its holdings in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after buying an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Price Performance

Shares of APLS stock opened at $29.93 on Wednesday. The stock has a 50 day moving average price of $31.88 and a 200 day moving average price of $33.35. Apellis Pharmaceuticals has a 52-week low of $24.34 and a 52-week high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm has a market capitalization of $3.72 billion, a P/E ratio of -14.74 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.17) earnings per share. As a group, sell-side analysts predict that Apellis Pharmaceuticals will post -1.73 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).